Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other Non-Current Assets (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Other Non-Current Assets for 16 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 21.3% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, down 21.3% year-over-year, with the annual reading at $4.0 million for FY2025, 21.3% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $4.0 million at Anika Therapeutics, down from $5.1 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $23.7 million in Q3 2021, with the low at $4.0 million in Q4 2025.
  • Average Other Non-Current Assets over 5 years is $16.4 million, with a median of $18.7 million recorded in 2021.
  • The sharpest move saw Other Non-Current Assets skyrocketed 78.97% in 2021, then plummeted 66.75% in 2023.
  • Over 5 years, Other Non-Current Assets stood at $20.3 million in 2021, then decreased by 15.11% to $17.2 million in 2022, then tumbled by 66.75% to $5.7 million in 2023, then dropped by 10.46% to $5.1 million in 2024, then dropped by 21.3% to $4.0 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $4.0 million, $5.1 million, and $11.3 million for Q4 2025, Q4 2024, and Q3 2024 respectively.